Sanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal

Published on August 30, 2021

Sanofi (SNY) and Regeneron (REGN)'s Dupixent meet all primary and secondary endpoints in phase III study to treat children aged six months to five yea...